Hepatitis Medicines
| Sofosbuvir | Sofosbuvir is a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase—the key enzyme mediating HCV RNA replication. The triphosphate form of sofosbuvir (GS-461203) mimics the natural cellular uridine nucleotide and is incorporated by the HCV RNA polymerase into the elongating RNA primer strand, resulting in viral chain termination. Sofosbuvir (available under brand names Sovaldi amongst others ) is in a class of anti-viral medications called nucleotide polymerase inhibitors. It is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). Sofosbuvir is proven to be extremely effective in treating hepatitis C genotypes 1, 2, 3 and 4 as part of combination therapy with other drugs like ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir.
|
| Ledipasvir | Ledipasvir is a potent inhibitor of HCV NS5A, a viral phosphoprotein that plays an important role in viral replication, assembly, and secretion. The fixed-dose combination of ledipasvir-sofosbuvir provides an effective and well-tolerated one-pill once-a-day option for treatment of genotypes 1, 4, 5, and 6 chronic hepatitis C (HCV) infection. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
|
| Daclatasvir | Daclatasvir is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 1 and genotype 3 infection. It is marketed under the name DAKLINZA and is contained in daily oral tablets as the hydrochloride salt form. Daclatasvir is used in combination with other drugs like sofosbuvir, ribavirin, and interferon, depending on the virus type and whether the person has cirrhosis.
|
| Tenofovir | Tenofovir disoproxil, sold under the trade name Viread among others, is a medication approved for use in adults with Hepatitis B or HIV. It belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs). It works by decreasing the amount of HIV and HBV in the blood. Although tenofovir will not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Tenofovir will not cure hepatitis B and may not prevent complications of chronic hepatitis B such as cirrhosis of the liver or liver cancer. It is generally recommended for use with other antiretrovirals.
|
| Velpatasvir+Sofosbuvir | Sofosbuvir-velpatasvir, available under the brand name EPCLUSA, is the first available pan genotypic NS5A-NS5B inhibitor single-pill combination regimen, and is highly efficacious across HCV genotypes 1 to 6. It provides a much-needed interferon-free option for patients with genotype 3 infection that is more economical than sofosbuvir plus daclatasvir. In patients who have compensated cirrhosis with genotype 3, this single-pill option provides an important ribavirin-free combination.
|
Hepatitis Medicines
FREE QUOTE
|
